HCAR2 and metabolic syndrome: In addition, SGLT2 inhibitors also inhibit the mechanistic target of rapamycin complex 1 (mTORC1) signaling overactivation by elevating ketone bodies in vivo, thereby attenuating non-proteinuric and proteinuric DKD (69).BHB inhibits adipocyte lipolysis via nicotinic acid receptor PUMA-G resulting in alleviation of dyslipidemia (76).